BSE Live
Mar 09, 10:48Prev. Close
1019.35
Open Price
1009.60
Bid Price (Qty.)
998.10 (3)
Offer Price (Qty.)
998.90 (60)
NSE Live
Mar 09, 10:48Prev. Close
1019.70
Open Price
1001.00
Bid Price (Qty.)
998.05 (36)
Offer Price (Qty.)
998.50 (57)
| Cash Flow of Natco Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 0.75 | 14.01 | |
| Net CashFlow From Operating Activities | 48.97 | 29.12 | |
| Net Cash Used In Investing Activities | -31.48 | -20.83 | |
| Net Cash Used From Financing Activities | 25.59 | -9.09 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 43.07 | -0.81 | |
| Cash And Cash Equivalents Begin of Year | 3.25 | 4.06 | |
| Cash And Cash Equivalents End Of Year | 46.33 | 3.25 |
09.03.2026
04.03.2026
Natco Pharma shares rise 2% on Pomalidomide capsules launch in US
16.02.2026
Natco Pharma shares rise over 11% after firm receives approval to launch Semaglutide in India
16.02.2026
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
14.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y